CDD Presenting at COMP Together, November 14 – Virtual

COMP Together Presents: An Evening with Barry Bunin and Eric Martin

Date: November 14, 2023

Time: 6:00 pm (Pizza & Drinks),  7:00 pm (Scientific Program)

Virtual: Available Via Zoom  Meeting ID: 948 5287 7895 Passcode: 293081

Join us for an exceptional evening of scientific dialogue and networking at the next COMP Together event! This special event features two esteemed speakers. Dr. Barry Bunin, CEO of CDD, will be presenting "Complementing the Medicinal Chemists’ Toolbox with Cloud-Based Deep Learning Models". Dr. Eric Martin of Novartis (who was a guest in our recent webinar) will also be presenting.

Don't miss this opportunity to dive into stimulating discussions that promise to expand your understanding of cutting-edge topics in medicinal chemistry and more. 

About the Speakers...

Barry Bunin, PhD

CEO, Collaborative Drug Discovery

Barry Bunin founded CDD in 2004 to pioneer CDD Vault, a hosted research data management system. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly, as well as the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). 

On the scientific side, Dr. Bunin is an expert in cheminformatics and combinatorial chemistry, and has written two books in those fields. He is also on the patent of Kyprolis, a selective proteasome inhibitor for treating multiple myeloma.

Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

Eric Martin, PhD

Director, Computational Chemistry at Novartis

Eric Martin has a Ph.D. in physical organic chemistry from Yale University. He has worked in computational drug design and herbicide design for 40 years at Dow, DowElanco, Chiron and Novartis. He is currently developing novel methodologies for two areas of drug discovery: 1)Developing “Profile-QSAR”, a massively multitask machine learning method that builds experimental-quality virtual screening models for over 9000 IC50 assays, and 2) “rational oral bioavailability design” during lead optimization, by applying global sensitivity analysis to physiologically-based pharmacokinetics simulations. Eric was awarded the lifetime title of Novartis Leading Scientist for the former.